Drug Shortage Report for PAPAVERINE HYDROCHLORIDE INJECTION USP

Last updated on 2022-06-17 History
Report ID 158046
Drug Identification Number 00009881
Brand name PAPAVERINE HYDROCHLORIDE INJECTION USP
Common or Proper name PAPAVERINE HCL
Company Name SANDOZ CANADA INCORPORATED
Market Status MARKETED
Active Ingredient(s) PAPAVERINE HYDROCHLORIDE
Strength(s) 65MG
Dosage form(s) LIQUID
Route of administration SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR
Packaging size 2ML 10LIVI
ATC code A03AD
ATC description DRUGS FOR FUNCTIONAL BOWEL DISORDERS
Reason for shortage Shortage of an inactive ingredient or component.
Anticipated start date 2022-02-11
Actual start date
Estimated end date 2022-09-02
Actual end date
Shortage status Actual shortage
Updated date 2022-06-17
Company comments Product is available on allocation at wholesalers, based on 75% of historical volumes.
Health Canada comments
Tier 3 Status Yes
Contact Address 110 RUE DE LAUZON
BOUCHERVILLE, QUEBEC
CANADA J4B 1E6
Company contact information 1 800-361-3062

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v14 2022-06-17 French Compare
v13 2022-06-17 English Compare
v12 2022-05-24 French Compare
v11 2022-05-24 English Compare
v10 2022-05-05 French Compare
v9 2022-05-05 English Compare
v8 2022-04-29 English Compare
v7 2022-04-20 French Compare
v6 2022-04-20 English Compare
v5 2022-04-06 French Compare
v4 2022-04-06 English Compare
v3 2022-04-06 French Compare
v2 2022-04-06 English Compare
v1 2022-04-06 English Compare

Showing 1 to 14 of 14